Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1998 1
1999 8
2000 4
2001 5
2002 7
2003 13
2004 8
2005 2
2006 11
2007 5
2008 3
2009 3
2010 3
2011 2
2013 6
2014 3
2015 4
2016 6
2017 4
2018 4
2019 3
2020 5
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 12087140

109 results

Results by year

Filters applied: . Clear all
Page 1
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML. Hamm CW, et al. N Engl J Med. 1999 May 27;340(21):1623-9. doi: 10.1056/NEJM199905273402103. N Engl J Med. 1999. PMID: 10341274 Free article. Clinical Trial.
Soluble CD40 ligand in acute coronary syndromes.
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML; CAPTURE Study Investigators. Heeschen C, et al. N Engl J Med. 2003 Mar 20;348(12):1104-11. doi: 10.1056/NEJMoa022600. N Engl J Med. 2003. PMID: 12646667 Free article. Clinical Trial.
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. James SK, et al. Circulation. 2003 Jul 22;108(3):275-81. doi: 10.1161/01.CIR.0000079170.10579.DC. Epub 2003 Jul 7. Circulation. 2003. PMID: 12847065 Clinical Trial.
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators. Cannon CP, et al. N Engl J Med. 2001 Jun 21;344(25):1879-87. doi: 10.1056/NEJM200106213442501. N Engl J Med. 2001. PMID: 11419424 Free article. Clinical Trial.
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
Damman P, Hirsch A, Windhausen F, Tijssen JG, de Winter RJ; ICTUS Investigators. Damman P, et al. J Am Coll Cardiol. 2010 Mar 2;55(9):858-64. doi: 10.1016/j.jacc.2009.11.026. Epub 2010 Jan 4. J Am Coll Cardiol. 2010. PMID: 20045278 Free article. Clinical Trial.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Akkerhuis KM, et al. Eur Heart J. 2000 Dec;21(24):2042-55. doi: 10.1053/euhj.2000.2309. Eur Heart J. 2000. PMID: 11102255 Clinical Trial.
109 results